Drawing for IMMUNOVIA

USPTO serial 79176585

IMMUNOVIA

Reviewed by CopyMark Law Group

Reg. 5197689Status 706Renewal
Filing date
Status date
Registration date
May 9, 2017
Examiner
PEETE, KYLE C
Law office
GENERIC WEB UPDATE

What this means

This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.

Need help with IMMUNOVIA?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $1,795*

Plus Government fees of $3,250

Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Anuj Desai

Anuj Desai Arnall Golden Gregory LLP171 17th Street NW, Suite 2100Atlanta, GA 30363United States

Goods and services

ClassDescriptionStatusFirst use
005Sanitary preparations for medical use; biological indicators for medical diagnosis; diagnostic preparations for medical purposes; diagnostic reagents for medical use; chemical reagents for medical purposes for the diagnosis of cancer and auto-immune diseasesACTIVE—
009Computer software for diagnosis of disease; computer software for diagnosing of cancer diseases; computer software for diagnosing of pancreatic cancer; computer software for diagnosing of breast cancer; computer software for diagnosing of prostate cancer; computer software for diagnosing of auto-immune diseases; DNA chipsACTIVE—
010Medical apparatus and instruments for diagnostic, prognostic patient stratification, examination and monitoring purposes, namely, apparatus for multiplex measuring of proteins in blood; diagnostic apparatus for medical purposes for diagnosing cancer and auto-immune diseases; sensor apparatus for medical use in diagnosis for diagnosing cancer and auto-immune diseases; apparatus for carrying-out diagnostic tests for medical purposes for diagnosing cancer and auto-immune diseases; medical diagnostic apparatus for detecting cancer and auto-immune diseases; DNA microarray for use in medical research for medical purposes for the diagnosis of cancer and auto-immune diseases; blood testing analyzers for medical purposes for the diagnosis of cancer and auto-immune diseasesACTIVE—
042Medical research services; scientific research for medical purposes in the area of cancerous diseases; scientific research for medical purposes in the area of pancreatic cancerous diseases; scientific research for medical purposes in the area of breast cancerous diseases; scientific research for medical purposes in the area of prostate cancerous diseases; scientific research for medical purposes in the area of auto-immune diseases; providing computer aided medical testing services, namely, computer aided blood analysis services in the field of cancer and auto-immune diseases research; research and development of computer softwareACTIVE—
044Performing diagnosis of diseases; medical services for the diagnosis of conditions of the human body; performing diagnosis of cancer and auto-immune diseasesACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
May 9, 2026REM4COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED—
Dec 25, 2025NREPNEW REPRESENTATIVE AT IB RECEIVED—
Sep 18, 2025RNWLINTERNATIONAL REGISTRATION RENEWED—
May 30, 2025NREPNEW REPRESENTATIVE AT IB RECEIVED—
Mar 7, 2025NREPNEW REPRESENTATIVE AT IB RECEIVED—
Feb 28, 2025TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Feb 28, 2025ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Feb 28, 2025REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Feb 28, 2025CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Feb 28, 2025COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Jan 4, 2024NA71NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED—
Jan 4, 202471AGREGISTERED-SEC.71 ACCEPTED—
Jan 3, 2024APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
May 4, 2023ES71TEAS SECTION 71 RECEIVED—
May 9, 2022REM3COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED—
Oct 20, 2017FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Aug 11, 2017FICSFINAL DISPOSITION NOTICE SENT TO IB—
Aug 11, 2017FIMPFINAL DISPOSITION PROCESSED—
Aug 9, 2017FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
May 9, 2017R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
May 5, 2017OPNXNOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB—
Apr 19, 2017OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Apr 19, 2017OPNRNOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB—
Feb 21, 2017NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Feb 21, 2017PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Feb 1, 2017NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Jan 16, 2017CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jan 16, 2017XAECEXAMINER'S AMENDMENT ENTERED—
Jan 16, 2017GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Jan 16, 2017GNEAEXAMINERS AMENDMENT E-MAILED—
Jan 16, 2017CNEAEXAMINERS AMENDMENT -WRITTEN—
Jul 16, 2016GNFNNOTIFICATION OF FINAL REFUSAL EMAILED—
Jul 16, 2016GNFRFINAL REFUSAL E-MAILEDA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Jul 16, 2016CNFRFINAL REFUSAL WRITTENA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Jun 14, 2016TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jun 14, 2016CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jun 14, 2016TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jan 4, 2016RFNPREFUSAL PROCESSED BY IB—
Dec 15, 2015RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Dec 15, 2015RFRRREFUSAL PROCESSED BY MPU—
Dec 15, 2015MAFRAPPLICATION FILING RECEIPT MAILED—
Dec 12, 2015RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Dec 11, 2015CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Dec 10, 2015DOCKASSIGNED TO EXAMINER—
Dec 10, 2015NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Dec 4, 2015REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance